Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

Diener H., Agosti R., Allais G., Bergmans P., Bussone G., Davies B., ...Daha Fazla

LANCET NEUROLOGY, cilt.6, sa.12, ss.1054-1062, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 12
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/s1474-4422(07)70272-7
  • Dergi Adı: LANCET NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1054-1062
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of topiramate after a treatment period of 6 months.